EP1862173A1 - Promotor der regeneration einer pankreatischen zelle und promotor der insulinproduktion in einer pankreatischen zelle - Google Patents

Promotor der regeneration einer pankreatischen zelle und promotor der insulinproduktion in einer pankreatischen zelle Download PDF

Info

Publication number
EP1862173A1
EP1862173A1 EP06714383A EP06714383A EP1862173A1 EP 1862173 A1 EP1862173 A1 EP 1862173A1 EP 06714383 A EP06714383 A EP 06714383A EP 06714383 A EP06714383 A EP 06714383A EP 1862173 A1 EP1862173 A1 EP 1862173A1
Authority
EP
European Patent Office
Prior art keywords
amino acid
peptide
residue
acid residue
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP06714383A
Other languages
English (en)
French (fr)
Other versions
EP1862173A4 (de
EP1862173B1 (de
Inventor
Kenji Kangawa
Takashi Akamizu
Taiga Irako
Shuichi Koda
Naomi Wakabayashi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyoto University
Daiichi Sankyo Co Ltd
Original Assignee
Kyoto University
Asubio Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36927405&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP1862173(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kyoto University, Asubio Pharma Co Ltd filed Critical Kyoto University
Publication of EP1862173A1 publication Critical patent/EP1862173A1/de
Publication of EP1862173A4 publication Critical patent/EP1862173A4/de
Application granted granted Critical
Publication of EP1862173B1 publication Critical patent/EP1862173B1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/60—Growth-hormone releasing factors (GH-RF) (Somatoliberin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
EP06714383.4A 2005-02-23 2006-02-23 Promotor der regeneration einer pankreatischen zelle und promotor der insulinproduktion in einer pankreatischen zelle Active EP1862173B1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2005046562 2005-02-23
JP2006003219 2006-01-11
PCT/JP2006/303243 WO2006090767A1 (ja) 2005-02-23 2006-02-23 膵臓β細胞の再生促進剤及び膵臓β細胞におけるインスリン産生促進剤

Publications (3)

Publication Number Publication Date
EP1862173A1 true EP1862173A1 (de) 2007-12-05
EP1862173A4 EP1862173A4 (de) 2012-03-28
EP1862173B1 EP1862173B1 (de) 2014-12-17

Family

ID=36927405

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06714383.4A Active EP1862173B1 (de) 2005-02-23 2006-02-23 Promotor der regeneration einer pankreatischen zelle und promotor der insulinproduktion in einer pankreatischen zelle

Country Status (11)

Country Link
US (1) US7803768B2 (de)
EP (1) EP1862173B1 (de)
JP (1) JP4843827B2 (de)
KR (1) KR101295104B1 (de)
CN (1) CN101128213B (de)
AU (1) AU2006216218B2 (de)
BR (1) BRPI0607475B8 (de)
CA (1) CA2598864C (de)
IL (1) IL184931A (de)
RU (1) RU2403058C2 (de)
WO (1) WO2006090767A1 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009040047A2 (en) * 2007-09-11 2009-04-02 Mondobiotech Laboratories Ag Therapeutic uses of ghrelin and combinations with stresscopin

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1197496A1 (de) * 1999-07-23 2002-04-17 Kenji Kangawa Neue peptide
WO2005039624A1 (en) * 2003-10-24 2005-05-06 Theratechnologies Inc. Use of ghrelin and unacylated ghrelin compostions in insulin-related disease conditions
WO2005114180A2 (en) * 2004-05-14 2005-12-01 Novo Nordisk A/S Functional ghs-r antagonists

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001228325A1 (en) 2000-02-01 2001-08-14 Novo-Nordisk A/S Use of compounds for the regulation of food intake
WO2002060472A1 (en) 2001-01-31 2002-08-08 Chugai Seiyaku Kabushiki Kaisha Remedies for hyponutrition status
EP1455814B1 (de) * 2001-12-18 2012-04-04 Alizé Pharma SAS Pharmazeutische zusammensetzungen enthaltend nicht-acyliertes ghrelin zur behandlung von insulinresistenz
MXPA05000160A (es) * 2002-07-05 2006-02-28 Chugai Pharmaceutical Co Ltd Producto terapeutico para la diabetes mellitus.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1197496A1 (de) * 1999-07-23 2002-04-17 Kenji Kangawa Neue peptide
WO2005039624A1 (en) * 2003-10-24 2005-05-06 Theratechnologies Inc. Use of ghrelin and unacylated ghrelin compostions in insulin-related disease conditions
WO2005114180A2 (en) * 2004-05-14 2005-12-01 Novo Nordisk A/S Functional ghs-r antagonists

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
F. BROGLIO: "Ghrelin, a Natural GH Secretagogue Produced by the Stomach, Induces Hyperglycemia and Reduces Insulin Secretion in Humans", JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, vol. 86, no. 10, 1 October 2001 (2001-10-01), pages 5083-5083, XP55019471, ISSN: 0021-972X, DOI: 10.1210/jc.86.10.5083 *
J. DONG: "Role of Endogenous Ghrelin in the Hyperphagia of Mice with Streptozotocin-Induced Diabetes", ENDOCRINOLOGY, vol. 147, no. 6, 1 June 2006 (2006-06-01), pages 2634-2642, XP55019469, ISSN: 0013-7227, DOI: 10.1210/en.2005-1335 *
See also references of WO2006090767A1 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009040047A2 (en) * 2007-09-11 2009-04-02 Mondobiotech Laboratories Ag Therapeutic uses of ghrelin and combinations with stresscopin
WO2009040047A3 (en) * 2007-09-11 2009-05-14 Mondobiotech Lab Ag Therapeutic uses of ghrelin and combinations with stresscopin

Also Published As

Publication number Publication date
US20090143284A1 (en) 2009-06-04
CN101128213A (zh) 2008-02-20
CA2598864A1 (en) 2006-08-31
IL184931A0 (en) 2007-12-03
AU2006216218B2 (en) 2011-08-11
BRPI0607475B1 (pt) 2020-02-11
JPWO2006090767A1 (ja) 2008-07-24
KR101295104B1 (ko) 2013-08-09
RU2007135225A (ru) 2009-03-27
CA2598864C (en) 2016-02-16
AU2006216218A1 (en) 2006-08-31
CN101128213B (zh) 2013-05-08
KR20070110856A (ko) 2007-11-20
JP4843827B2 (ja) 2011-12-21
IL184931A (en) 2011-08-31
EP1862173A4 (de) 2012-03-28
BRPI0607475B8 (pt) 2021-05-25
BRPI0607475A2 (pt) 2009-09-08
EP1862173B1 (de) 2014-12-17
RU2403058C2 (ru) 2010-11-10
US7803768B2 (en) 2010-09-28
WO2006090767A1 (ja) 2006-08-31

Similar Documents

Publication Publication Date Title
EP2694095B1 (de) Zusammensetzungen mit glukagon-analogen sowie verfahren zu ihrer herstellung und verwendung
EP3157949B1 (de) Exendin-4-derivate als selektive glucagonrezeptoragonisten
JP6606192B2 (ja) 抗肥満及び抗糖尿作用を有するペプチド及びその用途
EP2152297B1 (de) Nicht acyliertes ghrelin als therapeutikum zur behandlung von stoffwechselerkrankungen
JP4602075B2 (ja) 脳の健康に効果のあるインスリン関連ペプチド
EP3046573B1 (de) Amylin-analoga
JP2019214583A (ja) アシル化ｇｌｐ−１／ｇｌｐ−２二重アゴニスト
KR20170137198A (ko) 아실화된 글루카곤 유사체
EP3137494B1 (de) Inselamyloidpolypeptide mit verbesserter löslichkeit
JP6560462B2 (ja) 抗肥満及び抗糖尿病効能を有するペプチド及びその用途
US20140336109A1 (en) Modulation of ghrelin levels and ghrelin/unacylated ghrelin ratio using unacylated ghrelin
Barbier et al. Proinflammatory role of leptin in experimental colitis in rats Benefit of cholecystokinin-B antagonist and β3-agonist
JP4548335B2 (ja) 腸管細胞のインスリン産生細胞への変換誘導剤、及び糖尿病治療剤
US7803768B2 (en) Method for treatment of hyperglycemia in a subject in need thereof
US20070218504A1 (en) Human leptin-derived polypeptides and uses thereof
EP2391377A2 (de) Peptide, diese umfassende pharmazeutische zusammensetzungen und ihre verwendungen
CN115960258A (zh) 一类GLP-1/glucagon/Y2受体三重激动剂及其应用

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070820

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: DAIICHI SANKYO COMPANY, LIMITED

Owner name: KYOTO UNIVERSITY

A4 Supplementary search report drawn up and despatched

Effective date: 20120228

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 43/00 20060101ALI20120222BHEP

Ipc: A61K 38/22 20060101AFI20120222BHEP

Ipc: C07K 14/575 20060101ALI20120222BHEP

Ipc: A61P 3/10 20060101ALI20120222BHEP

17Q First examination report despatched

Effective date: 20121203

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20140625

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 701392

Country of ref document: AT

Kind code of ref document: T

Effective date: 20150115

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602006044010

Country of ref document: DE

Effective date: 20150205

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141217

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141217

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150318

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141217

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141217

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 701392

Country of ref document: AT

Kind code of ref document: T

Effective date: 20141217

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141217

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141217

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141217

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141217

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141217

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141217

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141217

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141217

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150417

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602006044010

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150223

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150228

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141217

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141217

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150228

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

26N No opposition filed

Effective date: 20150918

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141217

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 11

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150223

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141217

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141217

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 12

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20060223

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141217

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141217

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150417

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141217

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 13

REG Reference to a national code

Ref country code: DE

Ref legal event code: R081

Ref document number: 602006044010

Country of ref document: DE

Owner name: DAIICHI SANKYO CO., LTD., JP

Free format text: FORMER OWNERS: DAIICHI SANKYO CO., LTD., TOKYO, JP; KYOTO UNIVERSITY, KYOTO-SHI, KYOTO, JP

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20230110

Year of fee payment: 18

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

Free format text: REGISTERED BETWEEN 20230420 AND 20230426

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230515

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20231228

Year of fee payment: 19

Ref country code: GB

Payment date: 20240109

Year of fee payment: 19